Abstract
Abstract Background Low-density lipoprotein-cholesterol (LDL-C) is the main univariate risk marker recommended for initial atherosclerotic cardiovascular disease (ASCVD) risk stratification. LDL, however, transports other constituents that can serve as pro-atherogenic risk markers. Like LDL-C, the triglyceride content of LDL (LDL-TG) can also be estimated from the lipid panel. Using data from UK Biobank (UKB), we compared LDL-C to LDL-TG for predicting future ASCVD events. Methods A UKB dataset (N=270,436) of primary prevention individuals not on lipid lowering therapy was used for analysis. LDL-C was calculated by the following equations: Friedewald, Extended Martin-Hopkins, Sampson-NIH, and Enhanced Sampson-NIH. LDL-TG was calculated by our newly devised equation (eLDL-TG = TG/38.46 + nonHDL-C/5.75 + (TG/nonHDL-C)/0.103 + (1/HDL-C)/0.0041 - 2.95)), which was derived from a dyslipidemic cohort (N=40,202) analyzed by the beta-quantification reference method. Results Although there was only a modest comparison between eLDL-TG and measured LDL-TG (R2=0.601, slope=0.611), eLDL-TG appeared to be a better risk marker than LDL-C in UKB. When the population was divided into quintiles and analyzed by survival curve analysis, eLDL-TG was better than LDL-C in segregating patients into low- and high-risk groups (Figure). Similar findings on the relative value of LDL-TG over other risk markers were also found when analyzed by ROC analysis (AUC: eLDL-TG>HDL-C>remnant-cholesterol>NonHDL-C>TG>apoB>Sampson-NIH-LDL-C). By Cox-proportional hazard analysis eLDL-TG showed alongside apoB and NonHDL-C the strongest association with future ASCVD events. Discordance analysis showed that when stratified as LDL-TG/LDL-C as High/Low there was an 26% increased risk for ASCVD, and when as High/High showed an 40% increased risk for ASCVD. Conclusions Like LDL-C, LDL-TG levels can also be estimated from the standard lipid panel. If our findings hold in other populations, the superiority of LDL-TG over LDL-C as a risk marker suggest that the reporting of calculated LDL-TG along with LDL-C could be a new strategy for improving ASCVD risk stratification.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.